AbbVie
AbbVie to buy Botox-maker Allergan in USD 63 billion deal
Allergan shareholders will receive 0.8660 AbbVie shares and USD 120.30 in cash for each share held.
AbbVie rheumatoid arthritis drug succeeds in late stage trial
The U.S. drugmaker hopes the drug, upadacitinib, can help replace lost revenue from its top-selling RA treatment Humira.
1 of 1